SCHEMBL3748633

SCHEMBL3748633

COC(=O)c1nnc(-c2ccccc2)o1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.65
ALDH1A1 P00352 3/20 0.60
KDM4E B2RXH2 2/20 0.60
HPGD P15428 2/20 0.60
HSD17B10 Q99714 2/20 0.60
SMN1; SMN2 Q16637 3/20 0.58
GAA P10253 1/20 0.58
NPC1 O15118 6/20 0.53
RAB9A P51151 6/20 0.53
PKM P14618 1/20 0.53
MEN1 O00255 1/20 0.52
MAPT P10636 1/20 0.52
ALOX15 P16050 1/20 0.52
RECQL P46063 1/20 0.52
KMT2A Q03164 1/20 0.52
CES1 P23141 3/20 0.52
HDAC6 Q9UBN7 1/20 0.51
HIF1A Q16665 1/20 0.50
POLB P06746 1/20 0.50
TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31384301 0.85 KDM4E (0.61) PTPN1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL31384359 0.85 PKM (0.59) ALDH1A1KDM4ESMN1; SMN2GAANPC1
SCHEMBL114885 0.84 CA1 (0.67) PTPN1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5202186 0.83 NPC1 (0.68) PTPN1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL166289 0.83 POLB (0.67) PTPN1ALDH1A1KDM4EHSD17B10SMN1; SMN2
SCHEMBL31384371 0.83 HPGD (0.58) PTPN1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL4831697 0.83 SMN1; SMN2 (0.64) ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2
SCHEMBL31384335 0.83 HPGD (0.58) PTPN1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL12831210 0.82 PTPN1 (0.69) PTPN1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2330752 0.82 PTPN1 (0.93) PTPN1ALDH1A1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119504731-A Naringenin derivative containing 1,3, 4-oxadiazole acylhydrazone structure and preparation method thereof 广东省科学院测试分析研究所(中国广州分析测试中心) 2025-02-25 CN disclosed
US-7838543-B2 Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles ELI LILLY AND COMPANY (US) 2010-11-23 US disclosed
US-20090170913-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-07-02 US disclosed
EP-1828177-B1 NOVEL MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-08-13 EP disclosed
US-20080096931-A1 Oxadiazole ketone inhibitors of fatty acid amide hydrolase THE SCRIPPS RESEARCH INSTITUTE (US) 2008-04-24 US disclosed
US-20080096931-A1 Oxadiazole ketone inhibitors of fatty acid amide hydrolase THE SCRIPPS RESEARCH INSTITUTE (US) 2008-04-24 US disclosed
US-20080096931-A1 Oxadiazole ketone inhibitors of fatty acid amide hydrolase THE SCRIPPS RESEARCH INSTITUTE (US) 2008-04-24 US disclosed
US-7351724-B2 Oxadiazole ketone inhibitors of fatty acid amide hydrolase THE SCRIPPS RESEARCH INSTITUTE (US) 2008-04-01 US disclosed
US-7351724-B2 Oxadiazole ketone inhibitors of fatty acid amide hydrolase THE SCRIPPS RESEARCH INSTITUTE (US) 2008-04-01 US disclosed
US-7351724-B2 Oxadiazole ketone inhibitors of fatty acid amide hydrolase THE SCRIPPS RESEARCH INSTITUTE (US) 2008-04-01 US disclosed
EP-1828177-A2 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2007-09-05 EP disclosed
EP-1812427-A1 OXADIAZOLE KETONE INHIBITORS OF FATTY ACID AMIDE HYDROLASE The Scripps Research Institute (US) 2007-08-01 EP disclosed
WO-2006066173-A2 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2006-06-22 WO disclosed
US-20060100212-A1 Oxadiazole ketone inhibitors of fatty acid amide hydrolase THE SCRIPPS RESEARCH INSTITUTE (US) 2006-05-11 US disclosed
WO-2006044617-A1 OXADIAZOLE KETONE INHIBITORS OF FATTY ACID AMIDE HYDROLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100212-A1 Oxadiazole ketone inhibitors of fatty acid amide hydrolase FAAH, FAAH2, HCRTR2 PTPN1 4444/4885ALDH1A1 408/4885KDM4E 353/4885
US-20090170913-A1 NOVEL MCH RECEPTOR ANTAGONISTS MCHR1, MCHR2, MC1R PTPN1 812/4885ALDH1A1 1529/4885KDM4E 2042/4885
US-20080096931-A1 Oxadiazole ketone inhibitors of fatty acid amide hydrolase FAAH, FAAH2, HCRTR2 PTPN1 4444/4885ALDH1A1 408/4885KDM4E 353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.